Trusted Resource for Clinical Trials, Protocols & Progress
Good Laboratory Practice (GLP) is a quality system concerned with the organizational processes and conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived, and reported. It ensures the reliability and integrity of data generated for regulatory submissions across global agencies.
Click to read the full article.
Phase 0 trials, also known as microdosing studies, are the earliest phase of human clinical research. Introduced as part of an exploratory IND (Investigational New Drug) framework by the U.S. FDA, Phase 0 studies are designed to collect preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data in humans using very low doses of investigational drugs.
Click to read the full article.
A microdosing study involves the administration of extremely low, sub-therapeutic doses of a drug to human subjects to evaluate early pharmacokinetic (PK) and pharmacodynamic (PD) behavior. These studies fall under the category of Phase 0 clinical trials and are designed to provide rapid, human-specific data with minimal risk.
Click to read the full article.
Not every drug candidate is suitable for a Phase 0 microdosing study. These trials are designed to generate early pharmacokinetic (PK) and pharmacodynamic (PD) data without therapeutic intent. Therefore, selecting the right candidates is essential to ensure that the limited scope of Phase 0 delivers meaningful and predictive insights.
Click to read the full article.
Even though Phase 0 trials involve microdoses and no therapeutic intent, they are still clinical trials involving human participants. This means they must adhere to the highest ethical and safety standards. The fact that Phase 0 studies may offer no direct benefit to the subject makes ethical oversight even more critical.
Click to read the full article.
In Phase 0 trials, drug doses are so small that plasma concentrations are often in the picogram to nanogram range. This means standard analytical methods may not be sensitive enough to detect them. Therefore, the success of any microdosing study hinges on developing highly sensitive, specific, and validated bioanalytical assays.
Click to read the full article.
The main objective of most Phase 0 trials is to gather pharmacokinetic (PK) data in humans using microdose levels. These early insights help answer crucial questions such as: Is the drug absorbed? How long does it stay in circulation? Does it behave as expected?
Click to read the full article.
While Phase 0 studies are shorter and involve fewer participants than traditional trials, their setup requires meticulous planning and coordination. These trials often involve advanced technologies like microdosing, ultra-sensitive bioanalysis, and imaging endpoints, so having the right team, infrastructure, and subject management strategy is critical for success.
Click to read the full article.
Drug development is time-consuming and resource-intensive. Making informed go/no-go decisions as early as possible can prevent costly failures later. Phase 0 trials, through microdosing and focused pharmacokinetic/pharmacodynamic (PK/PD) evaluations, provide real-world human data to evaluate whether a drug candidate is worth advancing to Phase 1 and beyond.
Click to read the full article.
Phase 0 trials—or exploratory microdosing studies—may be low-risk, but they are still subject to stringent regulatory oversight. Each country has unique pathways for approval, risk classification, and ethical review. Understanding how agencies like the FDA (U.S.), EMA (Europe), CDSCO (India), and PMDA (Japan) approach Phase 0 trials is essential for global drug development planning.
Click to read the full article.
